Despite a bunch of way-too-late analyst downgrades (JPMorgan, Roth, Hapoalim) MDVN stock is up 1%+ at $13.25
on volume of 8.8M shares. But there are two interesting articles coming out of the Medivation drama:
Robert Langreth writing in Forbes offers the potential of better results on two upcoming trials and comments from Lon Schneider, an Alzheimer Disease expert from USC.
And John Jannarone writing in the WSJ asks if Big Pharma is too hungry for product so that small biotechs get the “upper hand” in deals.